Filing Flows › Comparisons › ADMA vs KRYS
Adma Biologics vs Krystal Biotech: ADMA and KRYS compared
Adma Biologics is the larger company: $141M of revenue in its latest quarter (Q3 2026) against $127M for Krystal Biotech (Q3 2026). Krystal Biotech is growing faster (+30% against +5% a year earlier). Krystal Biotech is more profitable, with an operating margin of 55.9% against 48.0%.
Where the money goes: ADMA and KRYS
Adma Biologics (ADMA) · Q3 2026
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Krystal Biotech (KRYS) · Q3 2026
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
| Adma Biologics (ADMA) | Krystal Biotech (KRYS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $141M | $127M |
| Revenue growth, Y/Y | +5% | +30% |
| Gross margin | 70.8% | — |
| Operating margin | 48.0% | 55.9% |
| Net earnings | $49.9M | $63.1M |
| Net margin | 35.4% | 49.5% |
| Operating cash flow | $17.4M | $91.2M |
| Free cash flow | $15.4M | $90.3M |
Questions
Which is bigger, Adma Biologics or Krystal Biotech?
Adma Biologics is the larger company: $141M of revenue in its latest quarter (Q3 2026) against $127M for Krystal Biotech (Q3 2026).
Is Adma Biologics or Krystal Biotech growing faster?
Krystal Biotech is growing faster (+30% against +5% a year earlier).
Which is more profitable, Adma Biologics or Krystal Biotech?
Krystal Biotech is more profitable, with an operating margin of 55.9% against 48.0%.
More: Adma Biologics earnings · how Adma Biologics makes money · Krystal Biotech earnings · how Krystal Biotech makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.